Good MorningThe equities markets made a small rebound on Wednesday but traders and investors shouldn’t read too much into the move. The S&P 500 gained about 0.75% at the high of the day while trading in a tight range near the low of the previous session. This is an indication of inherent market weakness and one that could lead to a much deeper decline for the market. If the S&P 500 continues to move lower and falls below the 4,300 level the market could take it down another 200 points or more.
The biggest risk this week is the PCE price index on Friday. If the index is hotter than the consensus figure, and there is every reason to think it will be, the onset of tapering at the next FOMC meeting is all but assured. Worse, for the stock market at least, is the fact tighter policy and interest rate hikes will soon follow.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Healthcare | |
Historically, the volume of insider selling tends to exceed that of insider buying. This is partly because when corporate executives and board members exercise granted stock options it is considered a sale activity. Then there are situations when insiders sell stock to diversify their personal por... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
You may not exactly talk about it outright, but do you have a sneaking suspicion that someone you care about hasn't made great strides in saving for retirement? In fact, the person you love might be grossly behind in saving for one of life's key financial must-dos.
You've got good reason for your... Read the Full Story |
|
Technology | | Cloud-based project management software Asana (NYSE: ASAN) celebrates one year as a public company on September 30. Since making its debut, priced at $21, shares are up more than 400%.
The stock tumbled along with the broader market Tuesday, dropping 10.30% to close at $102.25. Trading volume was 1... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | |
Perfect Positioning Is A Two-Edged Sword For Worthington
Worthington (NYSE: WOR) is perfectly positioned for the post-pandemic world. The company makes value-added steel products for manufacturing industries of all varieties, as well as consumer goods and materials for the construction industry. ... Read the Full Story |
|
Markets | |
Cintas Recovers Its Pre-COVID Revenue Levels
We can nit-pick the labor data all day long but one thing is clear in Cintas (NASDAQ: CTAS) Q1 results. Employment levels if not conditions have regained their pre-COVID levels. This is evident not only in the revenue but in the earnings and the outlo... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | | All-in-one video software solution Vimeo (NASDAQ: VMEO) stock is attempting to bottom out after being spun off from parent InterActiveCorp (NASDAQ: IAC). The Company was spun off from its parent in May 2021 and shares have since fallen sharply from a high of $57.88 to a low of $29.31. The company fo... Read the Full Story |
|
Finance | | IPO investing is without a doubt one of the most intriguing opportunities to pursue in the market. Choosing wisely can lead investors towards picking up shares of the next huge winner at low prices while taking a big position in a new public company that fails to find its footing will have investors... Read the Full Story |
|
Markets | | Electronic vehicle (EV) charging network Volta (NASDAQ: VLTA) stock surged after completing its reverse merger with Tortoise Acquisition Corp. II on Aug. 25, 2021. Shares initially sold off after the business combination starting trading under the new symbol as most special purpose acquisition compa... Read the Full Story |
|
Consumer Discretionary | |
There are not many things that are more disheartening to an investor than seeing the value of a particular holding move down sharply. And it can be even more concerning when downward price action coincides with a downgrade from the analyst community.
However, just as an analyst upgrade is not a... Read the Full Story |
|
Consumer Staples | |
Cal-Maine’s Dividend Outlook Brightens
We weren't expecting great results from Cal-Maine (NASDAQ: CALM) in the calendar third quarter, fiscal first, and we were partly right. The company posted a loss as expected but it was much less than forecast which is good news for those expecting a di... Read the Full Story |
|
The Early Bird Stock Of The Day Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. | | View Today's Stock Pick |
|
